Novel targeted mucosal vaccine delivery for viral pathogens using FcRn receptor

Engineered fusion proteins combine viral antigens and modified IgG Fc fragments to target the neonatal Fc receptor, enhancing mucosal delivery and inducing strong local and systemic immune responses against respiratory and other pathogens.

Background

The field of vaccine development has long relied on systemic immunization strategies that primarily target the bloodstream to stimulate immune responses. However, many pathogens enter the body through mucosal surfaces—areas not adequately protected by traditional vaccines. This disconnect highlights a significant need for improved strategies that can effectively induce both systemic and local immunity, especially for respiratory and other mucosal infections.

Current approaches often struggle to generate strong and durable immune responses at these critical entry points. Vaccines delivered by conventional methods may not sufficiently promote antigen uptake or the formation of tissue-resident immune cells necessary for long-term protection. Additionally, some methods can inadvertently trigger inflammatory responses or fail to activate the appropriate pathways for mucosal immunity. These limitations underscore the challenge of achieving comprehensive protection against pathogens that exploit mucosal routes, thereby necessitating innovative solutions to overcome the barriers inherent in traditional vaccine delivery systems.

Technology

This technology employs a fusion protein design that combines a modified Fc fragment with a viral antigen and a trimerization module to produce a stable, single-unit protein. The Fc segment is engineered by replacing specific cysteine residues to prevent dimerization and eliminate complement binding, while flexible linkers join it to both the antigenic domain and a stabilization element. Produced in CHO cells, the protein retains its pH-dependent binding to the neonatal Fc receptor, enabling efficient transport across mucosal barriers when delivered intranasally with an adjuvant to stimulate both systemic and localized immune responses.

What sets this platform apart is its targeted use of the natural FcRn pathway to facilitate antigen delivery directly across mucosal surfaces—a common shortfall of conventional vaccines. By harnessing this mechanism, the technology enhances immune cell activation and promotes the development of tissue-resident memory cells, leading to durable protection. Flexibility in design allows it to be adapted for several viral targets, making it a versatile and effective approach for eliciting broad and long-lasting immunity.

Benefits

  • Induces robust systemic and mucosal immune responses for comprehensive protection.
  • Utilizes FcRn-mediated transcytosis to enhance antigen uptake across mucosal barriers.
  • Incorporates engineered components (monomeric Fc, glycine-serine linkers, trimerization domain) to improve stability and minimize unwanted complement activation.
  • Demonstrates long-term immunity with memory cell formation, ensuring prolonged protection.
  • Offers broad applicability against diverse respiratory pathogens, including influenza, HSV-2, and SARS-CoV-2.

Applications

  • Intranasal vaccine formulation
  • Mucosal immunization platform
  • FcRn-targeted vaccine delivery
  • Respiratory pathogen vaccine

Additional info

This system comprises a fusion protein linking a modified monomeric Fc domain (with cysteine-to-serine changes eliminating dimer formation and complement binding) to an influenza HA extracellular region via glycine-serine linkers, further fused to a trimerization domain. Expressed in CHO cells, it binds the neonatal Fc receptor pH-dependently for mucosal epithelial transcytosis, thereby enhancing antigen presentation and eliciting robust local and systemic immune responses after intranasal administration with an adjuvant.